NCT05947448 - Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study | Biotech Hunter

Enrollment

1,215

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Essential Hypertension

Interventions

DRUG

Azilsartan Medoxomil Potassium Tablet

Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month

DRUG

Nifedipine Sustained -release Tablets

Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；

DRUG

Levoamlodipine Maleate Table

Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；

Trial Locations (1)

RECRUITING

Junbo Ge, Shanghai